Cargando…

Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro

PURPOSE: Receptor tyrosine kinase inhibitors (RTKIs) are used as targeted therapies for patients diagnosed with cancer with highly expressed receptor tyrosine kinases (RTKs), including the platelet-derived growth factor receptor (PDGFR) and c-Kit receptor. Resistance to targeted therapies is partial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourn, Jennifer, Cekanova, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005335/ https://www.ncbi.nlm.nih.gov/pubmed/29942116 http://dx.doi.org/10.2147/DDDT.S158518

Ejemplares similares

Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A
por: Bourn, Jennifer, et al.
Publicado: (2019)

Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells
por: Pandey, Sony, et al.
Publicado: (2018)

Detection of carcinogen-induced bladder cancer by fluorocoxib A
por: Bourn, Jennifer, et al.
Publicado: (2019)

Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro
por: Smolensky, Dmitriy, et al.
Publicado: (2015)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Receptor Tyrosine Kinase-Targeted Cancer Therapy
por: Yamaoka, Toshimitsu, et al.
Publicado: (2018)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo
por: Yu, Tao, et al.
Publicado: (2021)

Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies
por: Wei, Ying, et al.
Publicado: (2023)

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder
por: Lee, Young H., et al.
Publicado: (2021)

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
por: Hojjat-Farsangi, Mohammad
Publicado: (2014)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer
por: Cekanova, Maria, et al.
Publicado: (2020)

Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer
por: Smolensky, Dmitriy, et al.
Publicado: (2016)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
por: Abbaspour Babaei, Maryam, et al.
Publicado: (2016)

Role of tyrosine kinases in bladder cancer progression: an overview
por: Zangouei, Amir Sadra, et al.
Publicado: (2020)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
por: Russo, Eleonora, et al.
Publicado: (2021)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
por: Weiss, Johanna, et al.
Publicado: (2014)

Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
por: Park, Hyunjung, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells
por: Kang, Minyong, et al.
Publicado: (2017)

Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma
por: Liang, Linjun, et al.
Publicado: (2023)

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
por: Fleuren, Emmy D.G., et al.
Publicado: (2014)

Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer
por: Elferink, Lisa A., et al.
Publicado: (2011)

Animal model of naturally occurring bladder cancer: Characterization of four new canine transitional cell carcinoma cell lines
por: Rathore, Kusum, et al.
Publicado: (2014)

Tolerance of neurite outgrowth to Rho kinase inhibitors decreased by cyclooxygenase-2 inhibitor☆
por: Duan, Weigang, et al.
Publicado: (2012)

Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors
por: Molinari, Aurora, et al.
Publicado: (2019)

Design and profile of low-molecular-weight receptor tyrosine kinase inhibitors for antiangiogenic therapy
por: Wood, JM
Publicado: (2001)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
por: Gong, Juejun, et al.
Publicado: (2021)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
por: Masbuchin, Ainun Nizar, et al.
Publicado: (2022)

Molecular docking of 1H-pyrazole derivatives to receptor tyrosine kinase and protein kinase for screening potential inhibitors
por: Chandra,, et al.
Publicado: (2014)

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
por: Albarrán, Víctor, et al.
Publicado: (2022)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7ps4mavib159f106m7s194k778